EQRx links arms with In­sil­i­co on that two-let­ter buzz­word (AI); De­spite miss in pre­vi­ous­ly treat­ed pa­tients, Ri­bom­ic push­ing eye drug for­ward

An­oth­er deal has been inked in the ar­ti­fi­cial in­tel­li­gence-based drug dis­cov­ery land­scape, and it’s one fea­tur­ing a key play­er tout­ing the two-let­ter buzz­word fre­quent­ly, team­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER